Blocking one protein helps cancer cells die of natural causesJanuary 08, 2003Researchers have identified a protein fragment that keeps at least one major tumor suppressor gene from preventing cancer like it should. The fragment belongs to a class of proteins known as apoptotic enhancers (ASPP), named for their ability to stimulate programmed cell death, or apoptosis, by the p53 gene. But a study published in Nature Genetics finds that one member of this group, called iASPP, actually inhibits p53's normal cell killing power. When iASPP levels were reduced in experiments on different cell types, investigators found that the wild-type p53 gene could better suppress tumor cell growth, a strong sign that iASPP acts as a natural impediment to controlling cancer. "By all measures, it appears that iASPP plays a crucial role in turning normal cells into cancerous ones," said the study's lead author, Dr. Xin Lu, who is with the Ludwig Institute for Cancer Research, London St. Mary's Branch, and a professor at Imperial College London. "We can now target iASPP in further studies to potentially destroy tumors that express this gene." These results add to a growing list of attempts to attack cancer through the p53 corridor, one of the major genetic figures in controlling tumor growth. In a remarkably high number of cancers, the p53 gene is mutated and fails to work, allowing tumors to spread. The normal, or so-called wild-type versions of p53, are often disabled in cancer as well. For instance, the wild-type p53 gene fails to suppress tumors in 70% of breast cancers. An intriguing possibility for this poor success rate could be a mishap in the ASPP family. Like the poisonous snake asp that causes Cleopatra to die, ASPP enforces programmed cell death for wild-type p53: the three related proteins attach themselves to the tumor suppressor gene, controlling the on and off switch that signals malignant cells to essentially commit suicide. Two of the proteins (ASPP1 and ASPP2) stimulate the gene's suicidal demands, but now researchers are seeing an opposite effect in the third. When iASPP levels were lowered in worm and human cell lines, Dr. Lu's team found that p53 killed off more cells. Higher iASPP levels, on the other hand, caused the cells to become more resistant to the destructive effects of ultraviolet rays and the chemotherapy drug, cisplatin. Using specialized genetic techniques to block this protein, the researchers found that inhibiting iASPP could enhance the potential tumor suppressing abilities of p53 by as much as five-fold. "The amazing thing is that iASPP is not only an opponent of p53, but it must be a very important one since it has been doing the same job for millions of years," said Dr Lu. "These three ASPP proteins act as the Yin and Yang modulators of p53." | |||||||||||||||||||||
|
Related Cancer Current Events and Cancer News Articles Metabolic reactions: Less is more in single-celled organisms A Northwestern University study has found a surprising similarity among four quite different organisms. The simplest organism, a bacterium called H. pylori, uses the same number of biochemical reactions (around 300) as yeast, the largest, most complex organism of the group, when optimizing growth. Crystallography reveals the 3-D structure of mammalian sperm receptor Scientists at the Swedish medical university Karolinska Institutet have determined the first 3D structure of ZP3, a protein essential for the interaction between the mammalian egg coat and sperm. Dormant stem cells for emergencies Many specialized cells, such as in the skin, intestinal mucosa or blood, have a lifespan of only a few days. For these tissues to function, a steady replenishment of specialized cells is indispensable. This is the task of so-called "adult" stem cells also known as tissue stem cells. Bone marrow-derived stem cells may offer novel therapeutic option for skin disorder Stem cells derived from bone marrow may serve as a novel therapeutic option to treat a disease called epidermolysis bullosa (EB), a disorder characterized by extraordinarily fragile skin, according to a study prepublished online in Blood, the official journal of the American Society of Hematology. Interferon as long-term treatment for hepatitis C not effective, report HALT-C researchers Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study. Nursing study concludes few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genes An Ontario study of 491 women with invasive ovarian cancer found only a small proportion, 19%, were referred for genetic testing of BRCA1 and BRCA2, the breast cancer genes, which means family members are not informed of their cancer risk. Gene packaging tells story of cancer development To decipher how cancer develops, Johns Hopkins Kimmel Cancer Center investigators say researchers must take a closer look at the packaging. Researchers solve piece of large-scale gene silencing mystery A team led by Craig Pikaard, Ph.D., Washington University in St. Louis professor of biology in Arts & Sciences, has made a breakthrough in understanding the phenomenon of nucleolar dominance, the silencing of an entire parental set of ribosomal RNA genes in a hybrid plant or animal. Secondhand smoke raises odds of fertility problems in women If you need another reason to quit smoking, consider that it may diminish your chances of being a parent or grandparent. Scientists at the University of Rochester Medical Center have found that women exposed to second hand smoke, either as adults or children, were significantly more likely to face fertility problems and suffer miscarriages. Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer A genetic malfunction that causes DNA instability in people with the blood disorder Fanconi anemia may put them at high risk for squamous cell carcinomas linked to human papillomavirus (HPV), according to a study posted online ahead of print by Oncogene. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||